Go Pro
→ “This is the Perfect Tech Stock” (From Brownstone Research) (Ad)tc pixel
NASDAQ:AIMD

Ainos Q4 2025 Earnings Report

Ainos logo
$1.37 0.00 (0.00%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$1.37 0.00 (0.00%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ainos EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q4 2025
Date
3/30/2026
Time
After Market Closes
Conference Call Date
Monday, March 30, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q4 2025 Press ReleasePress Release
(8-K)
Ainos' Q4 2025 Annual reportAnnual report
(10-K)

Ainos Earnings Headlines

Ainos (NASDAQ:AIMD) Stock Price Down 4.9% - Here's Why
September 15 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31023617
Ainos shares rise 6.9% after receiving initial AI nose semiconductor orders
September 14 at 12:20 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/ainos-shares-rise-6-9-after-receiving-initial-ai-nose-semiconductor-orders/ar-AA2ccnCa
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
 |  Awesomely (Ad)
Ainos, Inc.: Ainos Secures Three Japanese Robotics Patents, Advancing Chemical Perception for the Physical AI Era
September 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69533381-ainos-inc-ainos-secures-three-japanese-robotics-patents-advancing-chemical-perception-for-the-physical-ai-era-200.htm
Ainos, Inc.: Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69353610-ainos-inc-ainos-launches-atmosphere-engine-extending-physical-ai-from-environmental-sensing-to-active-environmental-management-200.htm
Ainos Unveils Next-Generation AI Nose, Advancing the Infrastructure for Chemical Intelligence
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/ainos-unveils-next-generation-ai-130000100.html
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

View Ainos Profile
Earnings Tools